- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
Search Results
240 results for dgse
Novavax Stock Is a Buy Even After the Company’s Post-Dip Bounce
NVAX stock seems attractive for accumulation in the recent correction. Vaccine focus on low-income countries is likely to deliver growth.
Moderna Stock Is Worth Much More
Moderna reaps the rewards of its Covid-19 vaccine, and MRNA stock is worth 57% to 172% more based on near-term and long-term earnings power.
CureVac Is a Bet on a Safe and Effective Vaccine
CureVac is a bet on a winning Covid-19 vaccine that is effective and safe. Buying CureVac stock could produce a 27.5% annual compounded return over…
Pfizer May Have Found a New Hit Drug
The drug company’s new medication could be a game-changer. See what it treats and why one analyst thinks it’s a home run.
Ocugen Just Overcame a Serious Hurdle
OCGN stock has skyrocketed on positive Phase 3 results. But the company is facing tough competition.
The Vaccine Race Is Far From Over, And That’s Good News for Novavax
Bill Gates expects Novavax’s vaccine to be effective against Covid-19. Despite Pfizer being first, NVAX stock is still bound to benefit.
Revelation Biosciences (REVB) Stock Soars 120%
REVB stock is soaring 120%, but no news explains the rally. The firm recently finished dosing patients for a trial of its hay fever drug.
Alphabet Should Be on Every Technology Investor’s Radar Now
Skeptics might claim the Google search engine is “dead,” but a dose of common sense should get investors to lean bullish on GOOG stock.
Meet Your New Robot Overlords – Morning Linkfest (June 6)
InvestorPlace’s daily dose of some of the best reads elsewhere on Wall Street. Today’s top stories: robots, goats and junk bonds.
Wave Life Sciences News: WVE Stock Crashes 50% on Huntington’s Disease Data
Wave Life Sciences (WVE) news for Monday has WVE stock taking a beating on early data from its Huntington’s disease trial.
Covid-19 Vaccine Orders Are Piling Up, Moderna Stock Has Room to Grow
With production ramping to 1.4 billion doses and next-gen vaccine in trials, don’t underestimate Covid-19 vaccine upside for MRNA stock.
Novavax Stock is Set to Soar in the Year Ahead
The potential rewards in NVAX stock far outweigh the risks as the vaccine maker awaits regulatory approval from the WHO and others.
Moderna Is Ready To Rally After 2-Month Market Correction
MRNA stock is ready to rally once again, as the company gears up to deliver millions of Covid-19 vaccines in 2021 and help end this…
3 Electrical Equipment Stocks to Buy Now
This week, three electrical equipment stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall…
FDA Approves Ecstasy Trials for PTSD Sufferers
The Food and Drug Administration (FDA) has approved clinical trials for ecstasy to treat PTSD sufferers, including police and firefighters.
Novavax: Big Market Potential, Meaningful Stock Upside
Even after a 5,690% gain, NVAX stock looks positioned for further upside with the firm’s focus on bringing vaccines to low-income countries.
Novavax Stock Is Poised to Climb Further
NVAX stock seems positioned for further gains with the firm’s vaccine deliveries set to begin in early 2022.
Pfizer Looks Like Good Value With Its Vaccine Catalyst and Dividend Yield
Pfizer looks like good value with its vaccine catalyst and dividend yield. PFE stock will be 60% higher within several years after the FDA grants…
Moderna Is a Great Investment Despite Short-Term Headwinds
Following the FDA approval of its vaccine, MRNA stock is set to make some big gains on distribution deals across the globe.
If You’re Placing Bets on Vaccine Winners, Novavax Ought to Be on Your List
Novavax got a manufacturing partner in mid-September to make 2 billion doses. Despite NVAX stock going sideways since then, it remains a buy.
Ocugen Looks Very Dicey at Current Levels
Ocugen believes it can distribute 100 million doses of a Covid-19 vaccine in the U.S. But this looks like a long shot for OCGN stock.
5 – 10 of 240 results
